Seer, Inc. reported Q3 2025 revenue of $4.1 million, a 2% year-over-year increase, with a net loss of $18.2 million and a strong cash position of $251 million. The company achieved record third-party publications and significantly increased instrument shipments, nearly tripling year-to-date compared to all of 2024, driven by strong demand for its Proteograph ONE Assay and SP200 Automation Instrument, and its selection for a large NIH-funded multiomic study. Despite these operational successes and a $22 million share repurchase, Seer faces macroeconomic headwinds, including government funding uncertainty and CapEx constraints, leading to a full-year 2025 revenue guidance likely in the lower half of its $17 million to $18 million range, though management believes current cash is sufficient to reach cash flow breakeven.
Seer, Inc. reported Q3 2025 revenue of $4.1 million, a modest 2% year-over-year increase, alongside a net loss of $18.2 million. Despite these financial figures, the company demonstrated significant operational traction, achieving a record 13 third-party publications in the quarter and nearly tripling instrument shipments in the first nine months of 2025 compared to all of 2024. This growth was primarily driven by strong demand for the Proteograph ONE Assay and SP200 Automation Instrument, with almost two-thirds of instruments shipped this year being SP200s. Strategic initiatives like the Strategic Instrument Placement Program (SIPP) and the Seer Technology Access Center (STAC) are effectively lowering adoption barriers, evidenced by over two-thirds of Q3 instrument shipments going to prior STAC users. The expanded partnership with Thermo Fisher Scientific also yielded its first joint sale, signaling broader market penetration. Furthermore, Seer has utilized $21.9 million of its $25 million share repurchase program, reducing total shares outstanding by approximately 14%, reflecting management's belief in a significant share price dislocation. However, the company faces considerable macroeconomic headwinds, including ongoing government funding uncertainty, CapEx budget constraints, and the potential impact of a government shutdown on Q4 shipments. Consequently, Seer anticipates its full-year 2025 revenue will likely fall in the lower half of its $17 million to $18 million guidance range. Despite these challenges, the company maintains a robust cash position of $251 million, which management believes is sufficient to reach cash flow breakeven.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
